Theralase Technologies Inc.
TLT.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 293.20K | 254.10K | 73.70K | 130.20K | 267.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 293.20K | 254.10K | 73.70K | 130.20K | 267.30K |
| Cost of Revenue | 105.20K | 106.90K | 53.30K | 84.10K | 106.10K |
| Gross Profit | 188.00K | 147.20K | 20.40K | 46.10K | 161.20K |
| SG&A Expenses | 382.80K | 366.30K | 346.60K | 429.50K | 384.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 954.40K | 950.20K | 906.80K | 1.07M | 1.00M |
| Operating Income | -661.20K | -696.10K | -833.10K | -944.40K | -735.70K |
| Income Before Tax | -655.90K | -687.40K | -828.50K | -939.50K | -728.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -655.90K | -687.40K | -828.50K | -939.50K | -728.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -655.90K | -687.40K | -828.50K | -939.50K | -728.40K |
| EBIT | -661.20K | -696.10K | -833.10K | -944.40K | -735.70K |
| EBITDA | -629.10K | -663.40K | -801.30K | -911.50K | -700.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 256.41M | 234.62M | 231.89M | 229.47M | 226.39M |
| Average Diluted Shares Outstanding | 256.41M | 234.62M | 231.89M | 229.47M | 226.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
